TEMENOS
Temenos (SIX: TEMN), the banking software company, today announced that Orange Bank Africa has gone live with cloud-native Temenos Transact delivered as SaaS. Temenos Transact core banking technology scales to support the bank to launch and drive financial inclusion in the African WAEMU region, starting with the Ivory Coast. Temenos’ cloud technology enables sustainable, long-term growth for Orange Bank Africa by reducing IT costs, operational complexity and delivering an improved cost/income ratio.
Temenos and its partner, MCB Consulting, worked closely with Orange Bank Africa to implement the solution remotely after the onset of the Covid-19 pandemic. Temenos’ core banking technology is hosted on Microsoft Azure. Temenos’ SaaS technology and dedicated team support resulted in a seamless implementation within the original project timescales despite the global emergency. Temenos’ Model Bank approach provided highly localized, pre-configured banking functionality so the new software could be deployed quickly, without the need for customization.
Banking services penetration in West Africa is relatively low compared to mobile phone penetration, leaving significant room for expansion of mobile financial services. According to recent research from the Economist Intelligence Unit , the affordability of smartphones is driving the development of mobile-only and mobile-first initiatives, like Orange Bank Africa – this was cited as the top innovation strategy by 37% of MEA-based bank executives.
Orange Bank Africa’s mobile-first banking strategy was developed to deliver financial services to consumers’ phones. Temenos’ technology will allow Orange Bank Africa to continuously innovate and provide customers with much-needed access to savings accounts and micro-loans. The new technology drives process automation for these services in order to deliver vital funding to more people at a faster rate and promote financial inclusion.
Patrick Roussel, Vice President, MEA Mobile Financial Services at Orange, commented: “Our mission is to deliver banking services to those that don’t yet have access with an offer that differentiates us from the competition: simple, accessible and above all mobile-first banking. In order for us to achieve this goal in West Africa, we needed a strategic technology partner with rich experience deploying banking software in the cloud. Temenos’ cutting-edge cloud technology, relentless focus on innovation and unrivalled regional experience makes it the perfect partner for Orange Bank Africa as we launch our operations. Temenos Transact gives us the scalability we need to grow and provide vital financial services to millions of customers.”
Jean-Michel Hilsenkopf, Chief Operating Officer, Temenos, said: “Across the globe, banks are moving to the cloud and achieving operational excellence that drives a higher banking performance. For Orange Bank Africa, the cloud is key for rapid market expansion and sustainable business growth. There is a growing need to provide people in West Africa with access to banking services and Orange Bank Africa will play a vital role in addressing this. Telcos like Orange are particularly well placed to offer differentiated banking services and enhanced customer experiences because of their established client base and mobile-centric capabilities. Temenos’ SaaS technology provides a powerful and flexible solution that will support Orange Bank Africa to continuously adapt to changes in the market and innovate quickly as customer demands evolve. We are excited to support the bank in delivering personalized mobile-banking services as they advance financial inclusion in West Africa.”
– Ends –
About Orange Bank Africa
Orange Bank Africa is a digital bank, the result of a partnership between two international groups, Orange and NSIA, both present in Africa for many years. Orange Bank Africa’s ambition is to provide as many people as possible with a micro-credit and savings solutions, directly from their mobile phone, and in complete security.
Orange Bank Africa is based in Abidjan, Ivory Coast, and is set to expand to Burkina Faso, Mali and Senegal.
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200723005528/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom